MedTrace Logo

Role of Leucine on Muscle Preservation During Weight Loss in Older Men

NCT07781410 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-08-24

No results posted yet for this study

Summary

Overweight and obesity are part of a global health epidemic. However, older adults trying to lose weight face a dual challenge: first, muscle mass and strength naturally decline at an accelerating rate with age; second, effective weight loss diets like alternate-day fasting (ADF) are typically accompanied by significant muscle loss. Together, these factors can increase the risk of developing sarcopenia, a muscle disease characterized by critical losses in muscle mass and strength, especially when overweight or obese older adults try to lose weight through dieting alone. While high protein diets have often been advocated as a muscle preserving strategy when losing weight, recently, high leucine intake has been promoted for its critical role in stimulating muscle protein synthesis (MPS) with lower overall protein consumption, potentially reducing calorie intake while maintaining muscle during weight loss. Nonetheless, the effects of body mass-scaled protein and leucine intakes on muscular outcomes during weight loss remain uncertain. This study examines the effects of body mass-scaled protein and leucine supplementation on body composition during four weeks of ADF in older men.

Conditions

  • Overweight and Obese Adults
  • BMI>=23 kg/m2

Interventions

DIETARY_SUPPLEMENT

Placebo

Control (placebo supplements) 0.0 g/kg protein and 0.0 g/kg leucine supplementation per meal

DIETARY_SUPPLEMENT

Protein

Protein supplements: 0.4 g/kg protein and 0.04 g/kg leucine supplementation per meal

DIETARY_SUPPLEMENT

Leucine

Leucine supplementation: 0.0 g/kg protein and 0.08 g/kg leucine supplementation per meal

Sponsors & Collaborators

  • Ministry of Education, Singapore

    collaborator OTHER_GOV

  • Nanyang Technological University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-14
Primary Completion
2023-06-20
Completion
2023-06-20

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07781410 on ClinicalTrials.gov